PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary diseases. The Company's lead product candidate, PB2452, is a first-in-class ticagrelor reversal agent for the treatment of patients experiencing major bleeding and those who require urgent surgery. PB2452 was licensed from AstraZeneca in November 2017 and recently completed a Phase I clinical trial. PhaseBio's second product candidate, PB1046, is a once weekly, novel treatment for PAH, a life-threatening orphan disease caused by vasoconstriction and the progressive structural deterioration of the pulmonary arteries, which can lead to heart failure and, eventually, death. Results from a completed Phase Ib/IIa study in PAH patients show reductions in pulmonary arterial pressure and increases in cardiac output in patients receiving PB1046. The Company has initiated a Phase IIb trial of PB1046 in approximately 60 PAH patients